Application of Platelet-Rich Plasma in Gynaecologic Disorders: A Scoping Review
Date
2025
Authors
Willison, N.
Behnia-Willison, F.
Aryan, P.
Padhani, Z.A.
Mirzaei Damabi, N.
Nguyen, T.
Yi, J.
Dutta, R.
Abbott, D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Clinical Medicine, 2025; 14(16):5832-1-5832-20
Statement of Responsibility
Nadia Willison, Fariba Behnia-Willison, Pouria Aryan, Zahra Ali Padhani, Negin Mirzaei Damabi, Tran Nguyen, Johnny Yi, Rituparna Dutta, and Derek Abbott
Conference Name
Abstract
Platelet-rich plasma (PRP) therapy is a non-invasive, autologous treatment with regenerative potential in gynaecology beyond fertility applications. This review evaluates PRP in non-fertility-related gynaecological conditions affecting women’s quality of life (QoL). Methods: Following PRISMA-ScR guidelines, we searched Embase, CINAHL, Web of Science, Scopus, CENTRAL, and MEDLINE for studies on PRP in conditions such as vulvar lichen sclerosus (VLS), vulvovaginal atrophy (VVA), sexual dysfunction (SD), stress urinary incontinence (SUI), and interstitial cystitis/bladder pain syndrome (IC/BPS). Of 3660 records screened, 43 studies (randomised controlled trials, quasi-experimental, cohort, and case series) were included. Results: PRP improved symptoms and QoL in several conditions, particularly VLS and SD, and was generally well tolerated with minor adverse effects (e.g., injection-site pain, transient discomfort). Evidence for abnormal uterine bleeding (AUB) and pelvic organ prolapse (POP) was inconclusive. Considerable heterogeneity in preparation protocols and outcome measures limited cross-study comparison. Conclusions: PRP shows promise as a minimally invasive therapy for certain gynaecological conditions. Standardisation of preparation and administration, along with large-scale RCTs, is needed to determine long-term efficacy and safety.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).